TIM
AKBA icon

Tortoise Investment Management’s Akebia Therapeutics AKBA Stock Holding History

Tortoise Investment Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1,336
Closed -$13K – 548
2018
Q2 		$13K Buy
+1,336
New +$13.4K ﹤0.01% 378

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Tortoise Investment Management's AKBA Position: Q3 2018 in Review

Tortoise Investment Management sold out of Akebia Therapeutics (AKBA) in Q3 2018, closing a stake of 1,336 shares — an estimated $13K sold.

Tortoise Investment Management first reported a position in AKBA in Q2 2018 and held it in 1 quarter. The position peaked at $13K in Q2 2018. 130 funds tracked by Wall St. Rank hold AKBA as of Q3 2018.

  • Tortoise Investment Management reported no remaining Akebia Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Tortoise Investment Management sold 1,336 Akebia Therapeutics shares in Q3 2018, an estimated $13K.
  • Tortoise Investment Management first reported a position in Akebia Therapeutics in Q2 2018 and held it in 1 quarter.
  • Tortoise Investment Management's Akebia Therapeutics position peaked at $13K in Q2 2018.
  • 130 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2018.

Based on Tortoise Investment Management's 13F filing for Q3 2018, filed 20 Nov 2018.